Senno Therapeutics Accelerates Development of Cell Therapy Using iPS Cell-Derived Hepatoblast Cells

AI Summary (NQ-processed)

Senno Therapeutics, a Tokyo-based bioventure, is developing innovative cell therapies for fatal liver diseases using its proprietary allogeneic iPS cell-derived hepatoblast cells. Having raised 750 million JPY, the company plans to use the funds to advance non-clinical development and clinical trial preparations for its lead pipeline, SEN-001, aiming to address critical unmet medical needs in liver failure.